Download PDF
Zentralbl Chir 2006; 131(2): 134-139
DOI: 10.1055/s-2006-921552
Originalarbeiten und Übersichten

© Georg Thieme Verlag Stuttgart · New York

Fiktion und Fakten bei der multimodalen Therapie des Rektumkarzinoms

Fiction and Facts About Multi-Modal Therapy in Rectal CancerA. Ulrich1 , J. Weitz1 , H. Friess1 , M. Büchler1
  • 1Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Ruprecht-Karls-Universität, Heidelberg
Further Information

Publication History

Publication Date:
13 April 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfasung

Seit Einführung und Etablierung der totalen mesorektalen Exzision (TME) als chirurgisches Standard-Verfahren, hat sich die Prognose der Patienten mit einem Rektumkarzinom deutlich gebessert. So konnte allein durch die TME, unabhängig von multimodalen Therapiekonzepten, die Lokalrezidivrate auf unter 10 % gesenkt werden. Im Gegensatz dazu betrug sie vor der TME-Ära laut einer Deutschen Multizenterstudie noch im Jahre 1995 zwischen 4 und 55 % (Median 20 %). Ziel dieser Arbeit ist die Gegenüberstellung der multimodalen Therapiekonzepte mit ihren Ansprüchen sowie Vor- und Nachteilen anhand der in der aktuellen Literatur verfügbaren Daten. Neben der Lokalrezidivrate und der Überlebenszeit sollen auch die Toxizität, Kosten und Akzeptanz durch den Patienten betrachtet werden. Weiterhin soll aufgezeigt werden, wohin die Entwicklung der multimodalen Therapie derzeit tendiert, welche Konzepte bereits „Fakt” sind und welche wahrscheinlich „Fiktion” bleiben werden.

Abstract

The prognosis of patients with rectal cancer has been improved significantly after introduction of the total mesorectal excision (TME). Just by performing TME, the local recurrence rates could be decreased to less than 10 %, independent of multi-modal therapeutic concepts. In contrast, the local recurrence rate reached 4 to 55 % (median 20 %) in a German multicenter study in 1995 prior to the nationwide introduction of TME. The goal of this overview is to compare the different concepts in the multi-modal therapy of rectal cancer with their advantages and disadvantages based on the current literature. Mentioned will be local recurrence rates and survival, but also toxicity, costs and acceptance of patients. Furthermore, a preview is given about future developments.

Schlüsselwörter

Rektumkarzinom - TME - Strahlentherapie - multimodale Therapie - Kurzzeitstrahlentherapie

Key words

rectal carcinoma - total mesorectal excision - radiotherapy - multimodal treatment - short-term radiotherapy

Literatur

  • 1 Gastrointestinal Tumor Study Group . Prolongation of the disease-free interval in surgically treated rectal carcinoma.  N Engl J Med. 1985;  312 465-1472
    PubMedSearch in Google Scholar
  • 2 Stockholm Rectal Cancer Study Group . Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial.  Cancer. 1990;  66 49-55
    CrossrefPubMedSearch in Google Scholar
  • 3 Medical Research Council Rectal Cancer Working Party . Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer.  Lancet. 1996;  348 1605-1610
    CrossrefPubMedSearch in Google Scholar
  • 4 Stockholm Colorectal Cancer Study Group . Randomized study on preoperative radiotherapy in rectal carcinoma.  Ann Surg Oncol. 1996;  3 423-430
    CrossrefPubMedSearch in Google Scholar
  • 5 Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in resectable rectal cancer.  N Engl J Med. 1997;  336 980-987
    CrossrefPubMedSearch in Google Scholar
  • 6 Adjuvant radiotherapy for rectal cancer: a systematic overview of 8 507 patients from 22 randomised trials. Lancet 2001 358: 1291-1304
    Search in Google Scholar
  • 7 S3-Guidelines Colorectal Cancer 2004. Z Gastroenterol 2004 42: 1129-1177
    Search in Google Scholar
  • 8 Arnaud J P, Nordlinger B, Bosset J F, Boes G H, Sahmoud T, Schlag P M, Pene F. Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer.  Br J Surg. 1997;  84 352-357
    CrossrefPubMedSearch in Google Scholar
  • 9 Brown G, Kirkham A, Williams G T, Bourne M, Radcliffe A G, Sayman J, Newell R, Sinnatamby C, Heald R J. High-resolution MRI of the anatomy important in total mesorectal excision of the rectum.  AJR Am J Roentgenol. 2004;  182 431-439
    PubMedSearch in Google Scholar
  • 10 Buchler M W, Heald R J, Maurer C A, Ulrich B C. Rektumkarzinom: Das Konzept der Totalen Mesorektalen Exzision. Karger, Basel 1998
  • 11 Cecil T D, Sexton R, Moran B J, Heald R J. Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer.  Dis Colon Rectum. 2004;  47 1145-1150
    PubMedSearch in Google Scholar
  • 12 Crawshaw A, Hennigan T, Smedley F H, Leslie M D. Peri-operative radiotherapy for rectal cancer: the case for a selective pre-operative approach - the third way.  Colorectal Dis. 2003;  5 367-372
    CrossrefPubMedSearch in Google Scholar
  • 13 Dahlberg M, Glimelius B, Pahlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial.  Ann Surg. 1999;  229 493-497
    PubMedSearch in Google Scholar
  • 14 Douglass H O, Moertel C G, Mayer R J, Thomas P R, Lindblad A S, Mittleman A, Stablein D M, Bruckner H W. Survival after postoperative combination treatment of rectal cancer.  N Engl J Med. 1986;  315 1294-1295
    PubMedSearch in Google Scholar
  • 15 Frykholm G J, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects.  Dis Colon Rectum. 1993;  36 564-572
    CrossrefPubMedSearch in Google Scholar
  • 16 Frykholm G J, Sintorn K, Montelius A, Jung B, Pahlman L, Glimelius B. Acute lumbosacral plexopathy during and after preoperative radiotherapy of rectal adenocarcinoma.  Radiother Oncol. 1996;  38 121-130
    PubMedSearch in Google Scholar
  • 17 Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P, Bosset J F, Gignoux M, Arnaud J P, Desaive C. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).  Ann Surg. 1988;  208 606-614
    PubMedSearch in Google Scholar
  • 18 Glimelius B. Chemoradiotherapy for rectal cancer - is there an optimal combination?.  Ann Oncol. 2001;  12 1039-1045
    PubMedSearch in Google Scholar
  • 19 Glimelius B, Pahlman L. Perioperative radiotherapy in rectal cancer.  Acta Oncol. 1999;  38 23-32
    PubMedSearch in Google Scholar
  • 20 Havenga K, Enker W E, Norstein J, Moriya Y, Heald R J, Houwelingen H C, de Velde C J. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1 411 patients.  Eur J Surg Oncol. 1999;  25 368-374
    PubMedSearch in Google Scholar
  • 21 Hermanek P, Heald R J. Preoperative radiotherapy for rectal carcinoma? Has the case really been made for short course pre-operative radiotherapy if surgical standards for rectal cancer are optimal?.  Colorectal Dis. 2004;  6 10-14
    CrossrefPubMedSearch in Google Scholar
  • 22 Hermanek P, Wiebelt H, Staimmer D, Riedl S. German Study Group Colo-Rectal Carcinoma . Prognostic factors of rectum carcinoma - experience of the German Multicentre Study SGCRC.  Tumori. 1995;  81 60-64
    PubMedSearch in Google Scholar
  • 23 Horn A, Halvorsen J F, Dahl O. Preoperative radiotherapy in operable rectal cancer.  Dis Colon Rectum. 1990;  33 823-828
    PubMedSearch in Google Scholar
  • 24 Hyams D M, Mamounas E P, Petrelli N, Rockette H, Jones J, Wieand H S, Deutsch M, Wickerham L, Fisher B, Wolmark N. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.  Dis Colon Rectum. 1997;  40 131-139
    PubMedSearch in Google Scholar
  • 25 Kapiteijn E, Marijnen C A, Nagtegaal I D, Putter H, Steup W H, Wiggers T, Rutten H J, Pahlman L, Glimelius B, Krieken J H, Leer J W, de Velde C J. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.  N Engl J Med. 2001;  345 638-646
    CrossrefPubMedSearch in Google Scholar
  • 26 Krook J E, Moertel C G, Gunderson L L, Wieand H S, Collins R T, Beart R W, Kubista T P, Poon M A, Meyers W C, Mailliard J A. Effective surgical adjuvant therapy for high-risk rectal carcinoma.  N Engl J Med. 1991;  324 709-715
    CrossrefPubMedSearch in Google Scholar
  • 27 Kwok H, Bissett I P, Hill G L. Preoperative staging of rectal cancer.  Int J Colorectal Dis. 2000;  15 9-20
    CrossrefPubMedSearch in Google Scholar
  • 28 Letschert J G, Lebesque J V, de Boer R W, Hart A A, Bartelink H. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study.  Radiother Oncol. 1990;  18 307-320
    PubMedSearch in Google Scholar
  • 29 Marijnen C A, Kapiteijn E, de Velde C J, Martijn H, Steup W H, Wiggers T, Kranenbarg E K, Leer J W. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial.  J Clin Oncol. 2002;  20 817-825
    PubMedSearch in Google Scholar
  • 30 Marsh P J, James R D, Schofield P F. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial.  Dis Colon Rectum. 1994;  37 1205-1214
    PubMedSearch in Google Scholar
  • 31 Minsky B D. Adjuvant therapy for rectal cancer - a good first step.  N Engl J Med. 1997;  336 1016-1017
    PubMedSearch in Google Scholar
  • 32 Molls M. [Pre- and postoperative radiotherapy with and without chemotherapy in rectal cancer].  Chirurg. 1994;  65 569-575
    PubMedSearch in Google Scholar
  • 33 O'Connell M J, Martenson J A, Wieand H S, Krook J E, Macdonald J S, Haller D G, Mayer R J, Gunderson L L, Rich T A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.  N Engl J Med. 1994;  331 502-507
    CrossrefPubMedSearch in Google Scholar
  • 34 Overgaard M, Bertelsen K, Dalmark M, Gadeberg C C, von der Maase H, Overgaard J, Sell A. A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma.  Acta Oncol. 1993;  32 547-553
    PubMedSearch in Google Scholar
  • 35 Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.  Ann Surg. 1990;  211 187-195
    CrossrefPubMedSearch in Google Scholar
  • 36 Pahlman L, Glimelius B, Graffman S. Pre- versus postoperative radiotherapy in rectal carcinoma: an interim report from a randomized multicentre trial.  Br J Surg. 1985;  72 961-966
    PubMedSearch in Google Scholar
  • 37 Rodel C, Hohenberger W, Sauer R. [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status].  Strahlenther Onkol. 1998;  174 497-504
    PubMedSearch in Google Scholar
  • 38 Sauer R. Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer: first results of the German rectal cancer study (CAO/ARO/AIO-94).  Int J Radiat Oncol Biol Phys. 2003;  57 124-125
    PubMedSearch in Google Scholar
  • 39 Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess C F, Karstens J H, Liersch T, Schmidberger H, Raab R. German Rectal Cancer Study Group . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  351 1731-1740
    CrossrefPubMedSearch in Google Scholar
  • 40 Sauer R, Fietkau R, Wittekind C, Rodel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens J H, Becker H, Hess C, Raab R. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.  Colorectal Dis. 2003;  5 406-415
    PubMedSearch in Google Scholar
  • 41 Tveit K M, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, Nilsen J B, Wist E, Hannisdal E. Norwegian Adjuvant Rectal Cancer Project Group . Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer.  Br J Surg. 1997;  84 1130-1135
    CrossrefPubMedSearch in Google Scholar
  • 42 Ulrich A, Hartel M, Weitz J, Friess H, Buchler M W. Der Stellenwert der (neo-)adjuvanten Therapie beim Rektumkarzinom.  DMW. 2004;  129 957-962
    PubMedSearch in Google Scholar
  • 43 den Brink M, den Hout W B, Stiggelbout A M, Kranenbarg E K, Marijnen C A, de Velde C J, Kievit J. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: A study of the Dutch Colorectal Cancer Group.  J Clin Oncol. 2004;  22 244-253
    PubMedSearch in Google Scholar
  • 44 Zimmermann F, Molls M. Indikationen zur neoadjuvanten Therapie beim Rektumkarzinom.  Chirurg. 2003;  74 887-896
    CrossrefPubMedSearch in Google Scholar

Prof. Dr. med. Dr. h. c. M. W. Büchler

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie · Ruprecht-Karls-Universität Heidelberg

Im Neuenheimer Feld 110

69120 Heidelberg

Phone: 0 62 21/56 62 01

Email: markus_buechler@med.uni-heidelberg.de